Alnylam granted Zeltia's Sylentis S.A. subsidiary a non-exclusive option for a license to develop and commercialize a target-specific synthetic short interfering RNA to treat glaucoma

Alnylam Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$308.1m on 11/18/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Zeltia S.A.

Spain / Medical Devices and Diagnostics

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced